Feature | December 26, 2012

Congress Passes American Medical Isotope Production Act

SNMMI commends Sens. Jeff Bingaman and Lisa Murkowski for leadership

December 26 , 2012 — Congress last week affirmed its dedication to securing a sustainable, domestic supply of molybdenum-99 (Mo-99) as it passed the American Medical Isotope Production Act of 2011 (S.99). The bill, sponsored Sen. Jeff Bingaman (D-N.M.), chair of the Senate Committee on Energy and Natural Resources, and Sen. Lisa Murkowski (R-Ark), was passed out of the Senate by Unanimous Consent and referred to the House Subcommittee on Energy and Environment. S.99 was included in the Conference Agreement for the National Defense Authorization Act for fiscal year 2013. The president is expected to sign the final legislation.

The bill will establish a technology-neutral program to support the production of Mo-99 for medical uses in the United States by non-federal entities. It also calls for the United States to phase out the export of highly enriched uranium for the production of medical isotopes over a period of seven years.

“Sens. Bingaman and Murkowski have shown unwavering commitment to ensuring a stable isotope supply for the United States,” said Frederic H. Fahey, DSc, president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). “In order for our patients to receive the best medical care, it’s essential that a reliable supply of Mo-99 be available in the United States. We greatly appreciate their efforts in seeing this bill come to fruition.” Also instrumental in moving the legislation forward were Energy and Commerce Chair Fred Upton (MI-6) and Congressman Ed Markey (MA-7).

Mo-99 is an isotope that decays to technetium-99m (Tc-99m), which is used in more than 16.7 million procedures in the United States each year. Tc-99m is utilized in the detection of heart disease, detection and staging of cancer, detection of thyroid disease, study of brain and kidney function, and imaging of stress fractures.

There are currently only eight foreign producers of Mo-99 approved by the U.S. Food and Drug Administration to import the product into the United States — and there are no domestic facilities exist dedicated to the production of Mo-99 for medical uses. The aging foreign reactors regularly experience significant ongoing maintenance issues — frequently causing these reactors to go off-line. In 2009-2010, the Unites States experienced a shortage of Mo-99 that led to the disruption or delay of nuclear medicine procedures for an estimated 50,000 patients each day.

For more information: www.snmmi.org

Related Content

News | Radiopharmaceuticals and Tracers

June 24, 2022 — Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive ...

Home June 24, 2022
Home
News | Radiopharmaceuticals and Tracers

August 2, 2019 — The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) ...

Home August 02, 2019
Home
News | Radiopharmaceuticals and Tracers

July 16, 2019 – NorthStar Medical Radioisotopes LLC announced completion of construction on its 20,000-square-foot ...

Home July 16, 2019
Home
News | Radiopharmaceuticals and Tracers

June 5, 2019 – BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel ...

Home June 05, 2019
Home
News | Radiopharmaceuticals and Tracers

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular ...

Home May 17, 2019
Home
News | Radiopharmaceuticals and Tracers | Jeff Zagoudis, Associate Editor

May 10, 2019 — Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in ...

Home May 10, 2019
Home
News | Radiopharmaceuticals and Tracers

October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide ...

Home October 12, 2018
Home
Feature | Radiopharmaceuticals and Tracers | Dave Fornell

February 8, 2018 — The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) recently took ...

Home February 26, 2018
Home
News | Radiopharmaceuticals and Tracers

August 30, 2017 — ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary ...

Home August 30, 2017
Home
News | Radiopharmaceuticals and Tracers

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the ...

Home May 22, 2017
Home
Subscribe Now